SH003 + docetaxel

SH003 + docetaxel is a combination therapy consisting of SH003, a multi-herbal extract with anticancer properties, and docetaxel, a well-established taxane chemotherapy agent. \n- **SH003** is an investigational herbal mixture derived from Astragalus membranaceus (Huang-Qi), Angelica gigas (Dang-Gui), and Trichosanthes kirilowii (Gua-Lou-Gen). It has demonstrated anticancer effects through multiple mechanisms including inhibition of STAT3-IL-6 signaling, suppression of VEGF-induced angiogenesis via VEGFR2 inhibition, induction of autophagy and apoptosis in various cancer cell types (breast, prostate, cervical), and cell cycle arrest. \n- **Docetaxel** is a semisynthetic taxane that binds to tubulin in microtubules to promote their assembly while inhibiting disassembly. This stabilizes microtubules and disrupts mitosis leading to cell death. It is approved for use in breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head/neck cancers among others[6][8][10]. \nThe combination has shown synergistic antitumor activity in preclinical models by targeting EGFR activation pathways[1], enhancing efficacy against solid tumors such as lung cancer[3]. Clinical trials are ongoing to evaluate the safety profile and maximum tolerated dose for this combination in patients with solid cancers[7]. Additionally, SH003 may alleviate some adverse effects associated with docetaxel treatment such as chemotherapy-induced peripheral neuropathy by modulating neuroinflammatory markers like TNF-α and IL-6[5].

Other names

SH003 + docetaxel